Skip to main content

Table 3 Methylation status of NMDAR2B and clinicopathologic factors in clinical NSCLCs

From: Aberrant methylation of N-methyl-D-aspartate receptor type 2B (NMDAR2B) in non-small cell carcinoma

Cases (N = 216) Methylation (N = 131, 61%)
Gender Male (152) 93 (61) *
  Female (64) 38 (59)
Age** < 65 (107) 62 (58)
  ≥ 65 (109) 69 (63)
Smoking Never (64) 36 (56)
  Smoker (152) 95 (63)
Histology Adenocarcinoma (126) 68 (54)
  Others*** (90) 63 (70)
T factor T1 (135) 81 (60)
  T2, 3, 4 (81) 50 (62)
N factor N0 (115) 73 (63)
  N1, 2, 3 (101) 58 (57)
Stage I (80) 48 (60)
  II, III, IV (136) 83 (61)
  1. *Parentheses in each column indicate percentage of methylation
  2. **Divided by median age
  3. ***Others include squamous cell, adenosquamous cell, and large cell carcinoma